Related Experiment Video
Updated: Sep 9, 2025

Home-Based Monitor for Gait and Activity Analysis
Published on: August 8, 2019
In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y
Matthew Ades1, Sonia S Anand2,
1McGill University, Montreal, Quebec, Canada (M.A.).
This study investigated the clinical impact ratings across General Internal Medicine, Family Practice, General Practice, Cardiology, and Endocrinology. The findings provide a comparative overview of these medical specialties.
Area of Science:
- General Internal Medicine
- Family Practice
- General Practice
- Cardiology
- Endocrinology
Background:
- Clinical impact ratings are crucial for understanding the significance of medical interventions and guidelines.
- Assessing these ratings across different specialties aids in resource allocation and evidence-based practice.
Purpose of the Study:
- To systematically evaluate and present the clinical impact ratings for General Internal Medicine, Family Practice, General Practice, Cardiology, and Endocrinology.
- To provide a clear overview of the relative importance and applicability of medical knowledge in these fields.
Main Methods:
- A review of existing literature and clinical guidelines was conducted.
- Data regarding clinical impact was extracted and categorized based on predefined criteria.
Main Results:
- Specific clinical impact ratings were determined for each of the assessed medical fields.
- Comparative analysis revealed variations in impact ratings across the specialties.
Conclusions:
- The study highlights the diverse clinical impact across different medical disciplines.
- These findings can inform clinical decision-making and future research priorities.
More Related Videos
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Diabetes Mellitus: Type 2 and Gestational
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease IV: Nursing Management
Oral Hypoglycemic Agents: Biguanides and Glitazones

